Nifty50 today | Morgan Stanley maintains ‘equal weight’ rating on Dr Reddy’s Laboratories with target price of ₹1,215 per share.
Impurity of API No. 1 in validated lots of semaglutide delays commercial supply of injectable drugs
#2 No patient safety issues, product recalls or impact on existing regulatory approvals.
#3 The issue is limited to test lots and does not affect commercial shipments.
#4 Validation is expected to be completed by the end of the second quarter of FY2027, with commercial delivery to begin in the third quarter of FY2027.
#5 Management acknowledges strong demand, continued long-term strategy, and progress in identifying alternative API sources.
Dr Reddys Laboratories was quoted at Rs 1,247.45, down Rs 22.35 or 1.76 percent.
It touched an intraday high of Rs 1254.95 and an intraday low of Rs 1222.00.
Trading volume was 285,496 shares, compared with the five-day average of 130,023 shares, up 119.57 percent.